A brain in a dish

One of the major challenges in drug discovery is translating promising therapies from pre-clinical models – usually mice – to clinical use. The lack of suitable human pre-clinical models is a major roadblock for successful translation. To bridge the gap between animal models and human clinical trials new models of myelin damage and repair using human cells are crucial.

Recent advances in brain organoid culture has shown the viability of deriving myelinating brain organoids from human-induced pluripotent stem cells. However, one of the major limitations of brain organoids is the length of time required for organoids to reach a stage at which myelination is observed – often as long as 200 days. In a major advance, our collaborators have developed an innovative model for studying myelination in which mature myelin is observed after only 42 days. We will use this system as a basis for developing a sophisticated human pre-clinical model of demyelination and remyelination. Development of a human model of myelin damage and repair is a critical tool in bridging the gap between mouse models and human testing, providing an essential tool for prioritising candidates for clinical trial of remyelinating therapies.


  • Develop a human brain organoid pre-clinical model of demyelination and remyelination
  • Develop an immunocompetent human brain organoid pre-clinical model

Research team



Dr Sarrabeth Stone


Giovanni Pietrogrande – University of Queensland

Contact us

Dr Sarrabeth Stone

[email protected]